Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-07-10
2007-07-10
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S016700, C530S311000, C530S328000
Reexamination Certificate
active
10399542
ABSTRACT:
The present invention is directed to a novel class of cyclic polypeptides of the formula: (R1)a-AA1-cyclo[AA2-AA3-AA4-AA5-AA6-Cys]-AA7-R2, pharmaceutically acceptable salts thereof, wherein the variables are as defined in the specification, which inhibit the effects of urotensin-II and are useful for treating a variety of diseases and/or conditions characterized by an excess of urotensin-II including ischaemic heart disease, congestive heart failure, portal hypertension, variceal bleeding, hypotension, angina pectoris, myocardial infarction, ulcers, anxiety, schizophrenia, manic depression, delirium, dementia, mental retardation and/or dyskinesias.
REFERENCES:
patent: 6262229 (2001-07-01), Coy et al.
patent: 2002/0107187 (2002-08-01), Coy et al.
patent: 2004/0171530 (2004-09-01), Coy et al.
patent: 2004/0181032 (2004-09-01), Coy et al.
patent: 2 786 489 (2000-06-01), None
patent: WO 01/37780 (2001-05-01), None
Nishiki, M. et al., “Histopathological Improvement of Acromegalic Cardiomyopathy by Intermittent Subcutaneous Infusion of Octreotide,” Endocrine Journal, 1997, 44(5) :655-660.
Newby, D. E. et al., “Urotensin II: Better Than Somatostatin for Portal Hypertension?” Hepatology, 2000, 31(5) : 1201-1202.
Hocart, S. J. et al, “Highly Potent Cyclic Disulfide Antagonists of Somatostatin,” J. Medicinal Chem., 1999, 42(11) :1863-1871, XP002189091.
Hocart, S. J. et al. “Potent Antagonists of Somatostatin: Synthesis and Biology,” J. Medicinal Chem., 1998, 41:1146-1154, XP000749590.
Waugh, D. et al., “Purification and characterization of urotensin II from the brain of a teleost (trout,Oncorhynchus mykiss) and an elasmobranch (skate,Raja rhina),” Gen. and Comp. Endo., 1993, 92:419-427.
Coulouarn, Y. et al., “Cloning of the cDNA encoding urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneruons of the spinal cord,” PNAS, 1998, 95:15803-15808.
Coy David H.
Rossowski Wojciech J.
Taylor John E.
Feeney Alan F.
Russel Jeffrey Edwin
Societe de Conseils de Recherches et d'Applications Scientifique
The Administrators of the Tulane Educational Fund
Uhm Tony K.
LandOfFree
Urotensin-II agonists and antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Urotensin-II agonists and antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Urotensin-II agonists and antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3792256